A randomized phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8 Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4

• Unité de recherche: SIAK
• Numéro de projet: SAKK 35/98
• Titre du projet anglais: A randomized phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8 Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4

Mots-clé (Anglais)

SAKK Cancer oncology clinical trial Lymphoma CD20+ Rituximab Mabthera

Description succincte (Anglais)

A randomized phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8 Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4

Mise en oeuvre et application (Anglais)

Basis for evidence based oncological treatment

Publications / Résultats (Anglais)

first publication: annales of Oncology 11 (Suppl.1) : 123-126, 2000

Documents annexés

• M. Ghielmini et al.: Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK), Annals of Oncology 16: 1675–1682, 2005. [PDF] 192 kB

Adresses URL (Anglais)

http://www.siak.ch